In the Nasdaq composite, financial, consumer services and health-care sectors have seen their weightings more than double.» Read More
Steve Harris, CEO of Circassia, says his company is combating allergies by tackling how they affect people's immune systems, rather than simply making products that provide "symptomatic relief".
The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.
Bristol-Myers Squibb reported higher-than-expected earnings, helped by strong sales of its hepatitis C drugs and its Eliquis blood clot preventer.
Pfizer reported stronger-than-expected quarterly results as sales of vaccines and cancer drugs increased.
Cole Smead, portfolio manager at Smead Capital Management, discusses the strong U.S. dollar and how it will affect sectors like pharmaceuticals.
Novartis forecast sales and profits to grow at a faster pace this year driven by recent drug successes and its portfolio overhaul.
The ability to unfold a protein and return it to its original state could save money in everything from cancer research to food production.
A clinical trial of two experimental Ebola vaccines is expected to start in Liberia in the next couple of weeks, the NIH said.
Marvina is a premium cannabis provider that offers a monthly delivery service of marijuana to consumers in San Francisco.
Pharmaceutical giant Bristol-Myers Squibb named Dr. Giovanni Caforio as its new CEO on Tuesday.
The cost of a vaccination program is 68 times more expensive than is was in 2001. Doctors Without Borders wants companies to slash prices.
Discussing the current state of Europe at Davos 2015, Karl-Ludwig Kley, chairman of Merck says the lack of coordination and cohesion in European businesses is the current problem.Meanwhile political leaders need a wake-up call.
Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.
Johnson & Johnson reported lower-than-expected sales as a stronger dollar offset higher sales of the Band-Aid maker's new drugs and older treatments.
CNBC's Meg Tirrell and Leonard Schleifer, Regeneron president & CEO, talk about providing fair drug pricing for patients.
How much would it cost world governments to insulate their economies from global pandemics. Would you believe nearly $344 billion?
The Justice Department kept a secret database of incoming and outgoing U.S. international calls for more than a decade.
Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive $115 million to speed development.
Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.
Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.
Get the best of CNBC in your inbox